$TARS News

Tarsus to Participate in Upcoming Investor Conferences

Tarsus Q1 Review: Strong Earnings, But Wall Street Wanted A Guidance Raise

Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans

Tarsus Pharmaceuticals Collaborates With John Cena Over Eyelid Disease Demodex Blepharitis

Tarsus Pharmaceuticals, Inc. (TARS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Weakness And Long Term Gains

Is It Time To Reassess Tarsus Pharmaceuticals (TARS) After Its Recent Share Price Swings?

Tarsus Pharmaceuticals Q1 Earnings Call Highlights

Tarsus Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call Presentation

Tarsus Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary

Tarsus Pharmaceuticals Inc (NASDAQ:TARS) Beats Q1 Estimates with Explosive XDEMVY Growth But Stock Slips

Tarsus Pharmaceuticals, Inc. (TARS) Q1 2026 Earnings Call Transcript

Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements

HC Wainwright & Co. Reiterates Buy on Tarsus Pharmaceuticals, Maintains $88 Price Target

Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

Tarsus Pharmaceuticals: Marketing Spend Bears Fruit, Pipeline Progresses

Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Moves And Ongoing Losses

How TP-05’s Phase 2 Lyme Prophylaxis Trial Progress Could Impact Tarsus Pharmaceuticals (TARS) Investors

Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

Tarsus Pharma Says First Participant Dosed In Phase 2 Clinical Trial Evaluating TP-05, Investigational Oral Therapy To Prevent Lyme Disease By Killing Lyme-Infected Ticks Before Disease Transmission Occurs